Phase 3 Readout~month

Phase 3 Topline: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safe

Indication
IgA Nephropathy

Other upcoming events for BHVN

Phase 3 ReadoutPhase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficac
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefg

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safe — BHVN Phase 3 Readout | BioSniper